HPLC-UV determination of erdafitinib in mouse plasma and its application to pharmacokinetic studies

Elawady, Tarek; Khedr, Alaa; El‐Enany, N.; Belal, Fathalla

doi:10.1016/j.jchromb.2021.122629

Cited by 6 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the PK characteristics of the robust nanodrug were further assessed, and significantly improved PK parameters were observed. Specifically, when compared with the counterpart of pristine erdafitinib, the in vivo half-life and bioavailability (AUC) of the nanodrug increased by 8.3 times (14.4 h) and 5.0 times (8.0 μg/mL·h) in a mice model, respectively . PEG-COOH is believed to play an irreplaceable role in protecting the nanodrug from plasma albumin absorption and clearance by the mononuclear phagocytic system, thereby allowing an increase in the blood circulation time and bioavailability …”

Section: Resultsmentioning

confidence: 99%

“…The concentration of erdafitinib was detected by high-performance liquid chromatography (HPLC) as described in the literature. 36 …”

Section: Methodsmentioning

confidence: 99%

“…The concentration of erdafitinib was detected by high-performance liquid chromatography (HPLC) as described in the literature. 36 In Vivo and In Vitro Imaging of Tumor Xenografts. The tumor xenograft mice models were prepared using BALB/ c-nude mice.…”

Section: ■ Conclusionmentioning

confidence: 99%

See 2 more Smart Citations

Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy

Zhao

Jiang

et al. 2022

ACS Omega

View full text Add to dashboard Cite

Nanodrugs have attracted increasing interest in drug delivery and disease treatment. However, the cumbersome preparation process and the poor biocompatibility of nanodrugs obstruct their clinical translation. In this study, we utilized a self-assembly strategy to develop a low-toxicity, long-lasting nanodrug for the effective treatment and real-time monitoring of bladder tumors. The accurate self-assembly of compatible raw materials allowed for an encapsulation rate of 43.7% for insoluble erdafitinib. Interestingly, robust therapeutic effects and reduced side effects could be realized simultaneously using this nanodrug, enabling broader scenarios for the clinical application of erdafitinib. Furthermore, the nanodrug exhibited a significantly prolonged in vivo half-life (14.4 h) and increased bioavailability (8.0 μg/mL·h), which were 8.3 times and 5.0 times higher than those of its nonformulated counterpart. Also, it is worth mentioning that the introduction of a fluorescent protein module into the nanodrug brought up a novel possibility for real-time feedback on the therapeutic response. In conclusion, this research revealed a versatile technique for developing low-toxicity, long-acting, and multifunctional nanoformulations, paving the way for multidimensional therapy of malignant tumors.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The concentration of erdafitinib was detected by high-performance liquid chromatography (HPLC) as described in the literature. 36 …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy

Zhao

Jiang

et al. 2022

ACS Omega

View full text Add to dashboard Cite

show abstract

“…Patients with advanced or refractory solid tumors after treatment with different doses of erdafitinib, the exposure of erdafitinib increased in a dose-dependent manner, the median T max ranged from 2–3 h after the initial dose to 2–6 h after multiple daily dosing ( Nishina et al, 2018 ). After mice were given erdafitinib (30 mg/kg), C max was about 810 ng/ml and t 1/2 was about 1.73 h, and after mice were given erdafitinib (10 mg/kg), C max was about 110 ng/ml and t 1/2 was about 2.36 h ( Elawady et al, 2021 ). The PK results of this study showed that, after beagle dogs were given erdafitinib (4 mg/kg), C max was about 282 ng/ml, which was close to human C max when converted according to dose ( Poggesi et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

“…Consequently, it is necessary to invent and develop a method for the quantitative analysis of erdafitinib to evaluate the DDIs in pharmacokinetics. There were several literatures reported the pharmacokinetic profile of erdafitinib in patients using the LC-MS/MS methods ( Nishina et al, 2018 ; Bahleda et al, 2019 ; Poggesi et al, 2020 ) and the HPLC-UV method ( Elawady et al, 2021 ). On the basis of these reports, an ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method for detecting the concentration of erdafitinib in beagle dog plasma with bosutinib ( Figure 1B ) as internal standard (IS) was established and validated.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS

Ruan

Wang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: A robust, quick, and reliable ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method for the quantification of erdafitinib in beagle dog plasma was developed and validated to evaluate the changes of posaconazole and isavuconazole on the pharmacokinetics of erdafitinib in beagle dogs, respectively.Methods: This experiment adopted a three-period self-control experimental design. In the first period (group A), erdafitinib was orally administered to six beagle dogs at a dose of 4 mg/kg. In the second period (group B), the same six beagle dogs were orally given posaconazole at a dose of 7 mg/kg, and after 30 min, erdafitinib was orally given. In the third period (group C), isavuconazole at a dose of 7 mg/kg was given orally, and then, erdafitinib was orally given. At the different time points after erdafitinib was given in the three periods, the blood samples were collected. The concentration of erdafitinib was detected by the developed UPLC-MS/MS method. DAS 2.0 was used to calculate the pharmacokinetic parameters of erdafitinib.Results: Erdafitinib had a good linear relationship in the range of 1–500 ng/ml, and the lower limit of quantification was 1 ng/ml. The precision, accuracy, extraction recovery, matrix effect, and stability meet the requirements of the guiding principles. After erdafitinib was combined with posaconazole, the Cmax and AUC0→t of erdafitinib increased by 27.19% and 47.62%, respectively, and the t1/2 was prolonged to 6.33 h. After erdafitinib was combined with isavuconazole, the Cmax and AUC0→t of erdafitinib increased by 23.13% and 54.46%, respectively, and the t1/2 was prolonged to 6.31 h.Conclusion: A robust and reliable UPLC-MS/MS method was fully optimized and developed to detect the plasma concentration of erdafitinib in beagle dogs. Posaconazole and isaconazole could inhibit the metabolism of erdafitinib in beagle dogs and increase the plasma exposure of erdafitinib.

show abstract

Pioneering electrochemical detection unveils erdafitinib: a breakthrough in anticancer agent determination

Yildir,

Genc,

Erk

et al. 2024

Microchim Acta

View full text Add to dashboard Cite

The successful fabrication is reported of highly crystalline Co nanoparticles interconnected with zeolitic imidazolate framework (ZIF-12) -based amorphous porous carbon using the molten-salt-assisted approach utilizing NaCl. Single crystal diffractometers (XRD), and X-ray photoelectron spectroscopy (XPS) analyses confirm the codoped amorphous carbon structure. Crystallite size was calculated by Scherrer (34 nm) and Williamson-Hall models (42 nm). The magnetic properties of NPCS (N-doped porous carbon sheet) were studied using a vibrating sample magnetometer (VSM). The NPCS has a magnetic saturation (Ms) value of 1.85 emu/g. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) analyses show that Co/Co3O4 nanoparticles are homogeneously distributed in the carbon matrix. While a low melting point eutectic salt acts as an ionic liquid solvent, ZIF-12, at high temperature, leading cobalt nanoparticles with a trace amount of Co3O4 interconnected by conductive amorphous carbon. In addition, the surface area (89.04 m2/g) and pore architectures of amorphous carbon embedded with Co nanoparticles are created using the molten salt approach. Thanks to this inexpensive and effective method, the optimal composite porous carbon structures were obtained with the strategy using NaCl salt and showed distinct electrochemical performance on electrochemical methodology revealing the analytical profile of Erdatifinib (ERD) as a sensor modifier. The linear response spanned from 0.01 to 7.38 μM, featuring a limit of detection (LOD) of 3.36 nM and a limit of quantification (LOQ) of 11.2 nM. The developed sensor was examined in terms of selectivity, repeatability, and reproducibility. The fabricated electrode was utilized for the quantification of Erdafitinib in urine samples and pharmaceutical dosage forms. This research provides a fresh outlook on the advancements in electrochemical sensor technology concerning the development and detection of anticancer drugs within the realms of medicine and pharmacology. Graphical Abstract

show abstract

HPLC-UV determination of erdafitinib in mouse plasma and its application to pharmacokinetic studies

Cited by 6 publications

References 5 publications

Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy

Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS

Pioneering electrochemical detection unveils erdafitinib: a breakthrough in anticancer agent determination

Contact Info

Product

Resources

About